Cuardaigh le haghaidh roghanna malartacha:
evolves. » evolved. (Leathnaigh an cuardach), evolve. (Leathnaigh an cuardach)
revolvesdss. » revolveddss. (Leathnaigh an cuardach), revolvedss. (Leathnaigh an cuardach)
evolves. » evolved. (Leathnaigh an cuardach), evolve. (Leathnaigh an cuardach)
revolvesdss. » revolveddss. (Leathnaigh an cuardach), revolvedss. (Leathnaigh an cuardach)
-
221
Droplets as Cell Models: Chemical Gradient-Induced Directional Filopodia Formation
Foilsithe / Cruthaithe 2025Ábhair: -
222
Droplets as Cell Models: Chemical Gradient-Induced Directional Filopodia Formation
Foilsithe / Cruthaithe 2025Ábhair: -
223
Autocatalytic habitat with molecular parasite inflow (Model 2.2).
Foilsithe / Cruthaithe 2025Ábhair: -
224
-
225
Stabilized host-parasite-hyperparasite cycle with <i>K</i><sub><i>M</i></sub> in μM range.
Foilsithe / Cruthaithe 2025Ábhair: -
226
-
227
Autocatalytic habitat with molecular parasite exposure (Model 2.1).
Foilsithe / Cruthaithe 2025Ábhair: -
228
The alternative model 3.0.1 with reduced catalytic activity and <i>K</i><sub><i>M</i></sub> values in μM range.
Foilsithe / Cruthaithe 2025Ábhair: -
229
Autocatalytic habitat with molecular parasite exposure (Model 2.1).
Foilsithe / Cruthaithe 2025Ábhair: -
230
-
231
The null catalytic main model 3.1 with <i>K</i><sub><i>M</i></sub> values in μM range.
Foilsithe / Cruthaithe 2025Ábhair: -
232
-
233
Autocatalytic habitat with molecular parasite inflow (Model 2.2).
Foilsithe / Cruthaithe 2025Ábhair: -
234
The alternative model 3.0.2 with reduced catalytic activity and <i>K</i><sub><i>M</i></sub> values in 0.1 μM range.
Foilsithe / Cruthaithe 2025Ábhair: -
235
-
236
-
237
The null catalytic main model 3.2 and <i>K</i><sub><i>M</i></sub> values in 0.1 μM range.
Foilsithe / Cruthaithe 2025Ábhair: -
238
-
239
Stabilized host-parasite-hyperparasite cycle with <i>K</i><sub><i>M</i></sub> in 0.1 μM range.
Foilsithe / Cruthaithe 2025Ábhair: -
240
Trialblazers: “Build-a-Trial” workshops for people with psoriatic arthritis
Foilsithe / Cruthaithe 2024“…This was to be followed in June 2024 by an application to the Medical Research Council (MRC) funding stream for a grant in understanding public involvement in non-clinical research.</p><p dir="ltr">In collaboration with the NDORMS’ public-involvement group, Open Arms, and led by clinician researcher Laura Coates, the team developed and ran Build-a-Trial workshops with patients to design this much needed trial from scratch. …”